Figure 2

![Figure 2: Analysis of safety and efficacy data for commercially available CBD products, illustrating the lack of robust clinical evidence supporting health claims. The findings underscore regulatory and quality control concerns in the OTC cannabidiol market.]()

> Source: Edward Chesney et al. "Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol." *Therapeutic advances in psychopharmacology*, 2020. PMID: [32973998](https://pubmed.ncbi.nlm.nih.gov/32973998/)

<figure>
  <img src="" alt="Analysis of safety and efficacy data for commercially available CBD products, illustrating the lack of robust clinical evidence supporting health claims. The findings underscore regulatory and quality control concerns in the OTC cannabidiol market." />
  <figcaption>Figure 2. Analysis of safety and efficacy data for commercially available CBD products, illustrating the lack of robust clinical evidence supporting health claims. The findings underscore regulatory and quality control concerns in the OTC cannabidiol market.<br>  Source: Edward Chesney et al. "Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol." <em>Therapeutic advances in psychopharmacology</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32973998/">32973998</a></figcaption>
</figure>